Published in Nature on May 08, 1997
Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A (1997) 13.47
Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A (2003) 12.75
Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol (1999) 10.41
Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J Virol (2001) 7.37
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A (2008) 6.70
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects. Nat Med (2010) 5.36
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia. PLoS Pathog (2007) 4.82
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol (2003) 4.12
Comparative analysis of measures of viral reservoirs in HIV-1 eradication studies. PLoS Pathog (2013) 4.05
Neutralizing antibody responses drive the evolution of human immunodeficiency virus type 1 envelope during recent HIV infection. Proc Natl Acad Sci U S A (2005) 3.94
Kinetics of influenza A virus infection in humans. J Virol (2006) 3.78
Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A (2008) 3.71
Virus dynamics and drug therapy. Proc Natl Acad Sci U S A (1997) 3.63
HIV-infected individuals receiving effective antiviral therapy for extended periods of time continually replenish their viral reservoir. J Clin Invest (2005) 3.62
Persistent HIV-1 replication maintains the tissue reservoir during therapy. Nature (2016) 3.23
Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol (1999) 3.15
Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. J Virol (2004) 3.13
Latent reservoirs of HIV: obstacles to the eradication of virus. Proc Natl Acad Sci U S A (1999) 3.00
Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): Implications for HIV-1 infections of humans. Proc Natl Acad Sci U S A (2001) 2.96
Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci U S A (2003) 2.95
Hierarchical Bayesian methods for estimation of parameters in a longitudinal HIV dynamic system. Biometrics (2006) 2.95
Ultrasensitive reverse transcription-PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma. J Clin Microbiol (1998) 2.94
HIV latency. Cold Spring Harb Perspect Med (2011) 2.90
Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med (2010) 2.82
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Modelling the impact of antiretroviral use in resource-poor settings. PLoS Med (2006) 2.52
Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy. Clin Infect Dis (2010) 2.51
Epigenetic regulation of HIV-1 latency by cytosine methylation. PLoS Pathog (2009) 2.50
Evolution of envelope sequences of human immunodeficiency virus type 1 in cellular reservoirs in the setting of potent antiviral therapy. J Virol (1999) 2.42
Cellular reservoirs of HIV-1 and their role in viral persistence. Curr HIV Res (2008) 2.40
Viral sanctuaries during highly active antiretroviral therapy in a nonhuman primate model for AIDS. J Virol (2009) 2.37
Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol (2002) 2.32
Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest (2004) 2.30
Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection. Proc Natl Acad Sci U S A (2012) 2.27
Normal T-cell turnover in sooty mangabeys harboring active simian immunodeficiency virus infection. J Virol (2000) 2.26
Predicting the outcomes of treatment to eradicate the latent reservoir for HIV-1. Proc Natl Acad Sci U S A (2014) 2.23
Human immunodeficiency virus type 1 can establish latent infection in resting CD4+ T cells in the absence of activating stimuli. J Virol (2005) 2.23
Mutations in the tat gene are responsible for human immunodeficiency virus type 1 postintegration latency in the U1 cell line. J Virol (1998) 2.23
Genetic characterization of rebounding HIV-1 after cessation of highly active antiretroviral therapy. J Clin Invest (2000) 2.21
Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology (2009) 2.20
A simian immunodeficiency virus-infected macaque model to study viral reservoirs that persist during highly active antiretroviral therapy. J Virol (2009) 2.10
Orientation-dependent regulation of integrated HIV-1 expression by host gene transcriptional readthrough. Cell Host Microbe (2008) 2.08
Nuclear retention of multiply spliced HIV-1 RNA in resting CD4+ T cells. PLoS Pathog (2006) 2.08
Coalescent estimates of HIV-1 generation time in vivo. Proc Natl Acad Sci U S A (1999) 2.02
Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assay. PLoS Pathog (2013) 2.02
CD8+ lymphocytes control viral replication in SIVmac239-infected rhesus macaques without decreasing the lifespan of productively infected cells. PLoS Pathog (2010) 1.99
Parameter Estimation for Differential Equation Models Using a Framework of Measurement Error in Regression Models. J Am Stat Assoc (2008) 1.96
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother (2007) 1.91
Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol (2009) 1.89
Lack of detectable HIV-1 molecular evolution during suppressive antiretroviral therapy. PLoS Pathog (2014) 1.88
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads. J Virol (2004) 1.85
Latency in human immunodeficiency virus type 1 infection: no easy answers. J Virol (2003) 1.83
Expression of CCR5 increases during monocyte differentiation and directly mediates macrophage susceptibility to infection by human immunodeficiency virus type 1. J Virol (1998) 1.83
A stable latent reservoir for HIV-1 in resting CD4(+) T lymphocytes in infected children. J Clin Invest (2000) 1.81
Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART. PLoS Pathog (2007) 1.81
Quantifying the early immune response and adaptive immune response kinetics in mice infected with influenza A virus. J Virol (2010) 1.80
A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques. J Virol (1998) 1.79
Modeling latently infected cell activation: viral and latent reservoir persistence, and viral blips in HIV-infected patients on potent therapy. PLoS Comput Biol (2009) 1.78
Contribution of Vpu, Env, and Nef to CD4 down-modulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J Virol (2006) 1.77
A comparison of viral loads between HIV-1-infected elite suppressors and individuals who receive suppressive highly active antiretroviral therapy. Clin Infect Dis (2008) 1.76
Towards an HIV-1 cure: measuring the latent reservoir. Trends Microbiol (2015) 1.73
The risk of virologic failure decreases with duration of HIV suppression, at greater than 50% adherence to antiretroviral therapy. PLoS One (2009) 1.72
Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle. Proc Natl Acad Sci U S A (2008) 1.72
ON IDENTIFIABILITY OF NONLINEAR ODE MODELS AND APPLICATIONS IN VIRAL DYNAMICS. SIAM Rev Soc Ind Appl Math (2011) 1.69
A quantitative basis for antiretroviral therapy for HIV-1 infection. Nat Med (2012) 1.68
An integrated overview of HIV-1 latency. Cell (2013) 1.68
Modelling HIV immune response and validation with clinical data. J Biol Dyn (2008) 1.65
Evolutionary indicators of human immunodeficiency virus type 1 reservoirs and compartments. J Virol (2003) 1.62
Short-term administration of disulfiram for reversal of latent HIV infection: a phase 2 dose-escalation study. Lancet HIV (2015) 1.62
Frequent release of low amounts of herpes simplex virus from neurons: results of a mathematical model. Sci Transl Med (2009) 1.60
Dynamics of human immunodeficiency virus type 1 replication in vertically infected infants. J Virol (1999) 1.54
Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 1.54
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients. Antimicrob Agents Chemother (2002) 1.54
PCR-Based assay to quantify human immunodeficiency virus type 1 DNA in peripheral blood mononuclear cells. J Clin Microbiol (2000) 1.53
Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques. J Virol (1999) 1.52
Short-lived infected cells support virus replication in sooty mangabeys naturally infected with simian immunodeficiency virus: implications for AIDS pathogenesis. J Virol (2008) 1.51
Viral blip dynamics during highly active antiretroviral therapy. J Virol (2003) 1.51
Molecular mechanisms of HIV-1 persistence in the monocyte-macrophage lineage. Retrovirology (2010) 1.51
Integrated and Total HIV-1 DNA Predict Ex Vivo Viral Outgrowth. PLoS Pathog (2016) 1.50
Selection for human immunodeficiency virus type 1 recombinants in a patient with rapid progression to AIDS. J Virol (2002) 1.50
Persistent HIV-1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2002) 1.49
Modeling HIV persistence, the latent reservoir, and viral blips. J Theor Biol (2009) 1.49
Simian immunodeficiency virus SIVagm dynamics in African green monkeys. J Virol (2008) 1.49
Determination of virus burst size in vivo using a single-cycle SIV in rhesus macaques. Proc Natl Acad Sci U S A (2007) 1.48
Regulation of HIV-1 latency by T-cell activation. Cytokine (2007) 1.48
Can the viral reservoir of latently infected CD4(+) T cells be eradicated with antiretroviral HIV drugs? J Math Biol (2009) 1.47
Severe depletion of CD4+ CD25+ regulatory T cells from the intestinal lamina propria but not peripheral blood or lymph nodes during acute simian immunodeficiency virus infection. J Virol (2007) 1.47
A pilot study assessing the safety and latency-reversing activity of disulfiram in HIV-1-infected adults on antiretroviral therapy. Clin Infect Dis (2013) 1.46
HIV-1 Vpr enhances viral burden by facilitating infection of tissue macrophages but not nondividing CD4+ T cells. J Exp Med (2001) 1.45
5' long terminal repeat (LTR)-selective methylation of latently infected HIV-1 provirus that is demethylated by reactivation signals. Retrovirology (2006) 1.45
An in vitro rapid-turnover assay for human immunodeficiency virus type 1 replication selects for cell-to-cell spread of virus. J Virol (2000) 1.44
Agent-based modeling of host-pathogen systems: The successes and challenges. Inf Sci (Ny) (2009) 1.43
Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (1995) 34.97
Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol (1994) 22.96
HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science (1996) 21.81
Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science (1997) 18.10
Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Exp Med (1999) 14.30
Genotypic and phenotypic characterization of HIV-1 patients with primary infection. Science (1993) 13.87
Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell (1994) 13.76
Quantitation of HIV-1-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science (1998) 12.05
The role of a mutant CCR5 allele in HIV-1 transmission and disease progression. Nat Med (1996) 10.62
Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol (1993) 8.62
Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. N Engl J Med (1995) 8.23
Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. N Engl J Med (1991) 7.83
Adaptive evolution of human immunodeficiency virus-type 1 during the natural course of infection. Science (1996) 7.73
Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science (2001) 7.66
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med (1999) 7.07
Isolation of HTLV-III from cerebrospinal fluid and neural tissues of patients with neurologic syndromes related to the acquired immunodeficiency syndrome. N Engl J Med (1985) 6.54
High concentrations of recombinant soluble CD4 are required to neutralize primary human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci U S A (1990) 6.49
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol (1995) 6.33
Analysis of gene expression in single live neurons. Proc Natl Acad Sci U S A (1992) 6.15
Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med (1996) 6.14
Infection of monocyte/macrophages by human T lymphotropic virus type III. J Clin Invest (1986) 5.90
Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med (1996) 5.63
Cellular targets of infection and route of viral dissemination after an intravaginal inoculation of simian immunodeficiency virus into rhesus macaques. J Exp Med (1996) 5.35
Genome sequence of the plant pathogen and biotechnology agent Agrobacterium tumefaciens C58. Science (2001) 5.16
Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol (1987) 5.03
Increased viral burden and cytopathicity correlate temporally with CD4+ T-lymphocyte decline and clinical progression in human immunodeficiency virus type 1-infected individuals. J Virol (1993) 4.83
HTLV-III in the semen and blood of a healthy homosexual man. Science (1984) 4.53
Declining blood lead levels and cognitive changes in moderately lead-poisoned children. JAMA (1993) 4.46
A branched DNA signal amplification assay for quantification of nucleic acid targets below 100 molecules/ml. Nucleic Acids Res (1997) 4.40
Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis. Lancet (1999) 4.36
Induction of anti-HIV neutralizing antibodies by synthetic peptides. EMBO J (1986) 4.32
Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci U S A (2000) 4.22
The decay of the latent reservoir of replication-competent HIV-1 is inversely correlated with the extent of residual viral replication during prolonged anti-retroviral therapy. Nat Med (2000) 4.08
Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J (1997) 4.07
Antibodies to discontinuous or conformationally sensitive epitopes on the gp120 glycoprotein of human immunodeficiency virus type 1 are highly prevalent in sera of infected humans. J Virol (1993) 3.95
Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell (1996) 3.88
Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J Virol (1999) 3.79
Discontinuous, conserved neutralization epitopes overlapping the CD4-binding region of human immunodeficiency virus type 1 gp120 envelope glycoprotein. J Virol (1992) 3.79
Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection. AIDS Res Hum Retroviruses (1996) 3.74
Genetic diversity of human immunodeficiency virus type 2: evidence for distinct sequence subtypes with differences in virus biology. J Virol (1994) 3.70
An African HIV-1 sequence from 1959 and implications for the origin of the epidemic. Nature (1998) 3.69
Time to hit HIV, early and hard. N Engl J Med (1995) 3.53
HIV-1 drug resistance in newly infected individuals. JAMA (1999) 3.49
Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol (1996) 3.48
Pathogenesis of infection with human immunodeficiency virus. N Engl J Med (1987) 3.45
Modeling plasma virus concentration during primary HIV infection. J Theor Biol (2000) 3.40
Rapid turnover of T lymphocytes in SIV-infected rhesus macaques. Science (1998) 3.39
Photoinduced conversion of silver nanospheres to nanoprisms. Science (2001) 3.39
Increased turnover of T lymphocytes in HIV-1 infection and its reduction by antiretroviral therapy. J Exp Med (2001) 3.37
Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry. J Virol (1997) 3.33
Development of the anti-gp120 antibody response during seroconversion to human immunodeficiency virus type 1. J Virol (1994) 3.28
Use of real-time PCR and molecular beacons to detect virus replication in human immunodeficiency virus type 1-infected individuals on prolonged effective antiretroviral therapy. J Virol (1999) 3.15
A chemokine receptor CCR2 allele delays HIV-1 disease progression and is associated with a CCR5 promoter mutation. Nat Med (1998) 3.15
Identification and characterization of a neutralization site within the second variable region of human immunodeficiency virus type 1 gp120. J Virol (1992) 3.13
HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells. AIDS (1995) 3.08
Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol (1995) 3.05
Recombinant human interferon alfa-A suppresses HTLV-III replication in vitro. Lancet (1985) 3.03
Human immunodeficiency virus type 1 variants with increased replicative capacity develop during the asymptomatic stage before disease progression. J Virol (1994) 3.01
Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of human immunodeficiency virus type 1 gp120. J Virol (1989) 3.00
Spectral genotyping of human alleles. Science (1998) 2.95
Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci U S A (1997) 2.88
Spinal cord repair in adult paraplegic rats: partial restoration of hind limb function. Science (1996) 2.83
Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression. Nature (2001) 2.83